TY - JOUR
T1 - Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge
AU - Taylor, David N.
AU - McKenzie, Robin
AU - Durbin, Anna
AU - Carpenter, Colleen
AU - Atzinger, Christophe B.
AU - Haake, Robert
AU - Bourgeois, A. Louis
PY - 2006/5/1
Y1 - 2006/5/1
N2 - Background. This double-blind, placebo-controlled study was conducted to assess the efficacy of the non-absorbed oral antibiotic rifaximin to prevent shigellosis in volunteers challenged with Shigella flexneri. Methods. Volunteers were randomized to receive either prophylactic rifaximin (200 mg 3 times daily for 3 days; n = 15) or placebo (n = 10) on days 0, 1, and 2. On day 1, volunteers were challenged with ∼1500 colonyforming units of S. flexneri 2a strain 2457T given orally in sodium bicarbonate buffer. Results. The incidence of diarrhea was 0 with rifaximin, compared with 60% with placebo (P = .001). The median time to onset of diarrhea was 78.5 h with placebo (P < .001). The incidence of dysentery was 0 for rifaximin and 10% for placebo (P = .4). The incidence of colonization with Shigella was 0 with rifaximin, compared with 50% with placebo (P< .005). A significant serum or mucosal immune response after challenge by at least 1 indicator (immunoglobulin A titer, immunoglobulin G titer, and immunoglobulin A antibody-secreting cell count) was 0 with rifaximin and 80% with placebo (P<.001). Conclusions. Rifaximin was effective and well tolerated, compared with placebo, in preventing shigellosis in this double-blind study of volunteers challenged with S. flexneri 2a.
AB - Background. This double-blind, placebo-controlled study was conducted to assess the efficacy of the non-absorbed oral antibiotic rifaximin to prevent shigellosis in volunteers challenged with Shigella flexneri. Methods. Volunteers were randomized to receive either prophylactic rifaximin (200 mg 3 times daily for 3 days; n = 15) or placebo (n = 10) on days 0, 1, and 2. On day 1, volunteers were challenged with ∼1500 colonyforming units of S. flexneri 2a strain 2457T given orally in sodium bicarbonate buffer. Results. The incidence of diarrhea was 0 with rifaximin, compared with 60% with placebo (P = .001). The median time to onset of diarrhea was 78.5 h with placebo (P < .001). The incidence of dysentery was 0 for rifaximin and 10% for placebo (P = .4). The incidence of colonization with Shigella was 0 with rifaximin, compared with 50% with placebo (P< .005). A significant serum or mucosal immune response after challenge by at least 1 indicator (immunoglobulin A titer, immunoglobulin G titer, and immunoglobulin A antibody-secreting cell count) was 0 with rifaximin and 80% with placebo (P<.001). Conclusions. Rifaximin was effective and well tolerated, compared with placebo, in preventing shigellosis in this double-blind study of volunteers challenged with S. flexneri 2a.
UR - http://www.scopus.com/inward/record.url?scp=33646076468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646076468&partnerID=8YFLogxK
U2 - 10.1086/503039
DO - 10.1086/503039
M3 - Article
C2 - 16586388
AN - SCOPUS:33646076468
SN - 1058-4838
VL - 42
SP - 1283
EP - 1288
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 9
ER -